S. Graber

Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration

M. Koury, S. Koury, J. Caro, 1989 .

Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial.

J. Adamson, E. Friedman, A. Nissenson, 1989, Annals of internal medicine.

Cost Effectiveness of Two Interventions for Reducing Outpatient Prescribing Costs

S. Graber, D. T. Bess, M. Steele, 1989, DICP : the annals of pharmacotherapy.

Erythropoietin messenger RNA levels in developing mice and transfer of 125I-erythropoietin by the placenta.

M. Koury, M. Bondurant, S. Graber, 1988, The Journal of clinical investigation.

Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration.

M. Koury, S. Koury, J. Caro, 1989, Blood.

Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients.

J. Egrie, S. Graber, J. Lazarus, 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US Recombinant Human Erythropoietin Predialysis Study Group.

E. Friedman, M. Rudnick, S. Graber, 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis.

J. Egrie, S. Graber, D. Goodkin, 1999, Clinical Nephrology.